{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T18:37:18Z","timestamp":1793471838065,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jaccao.2022.06.004","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T18:14:59Z","timestamp":1663697699000},"page":"371-383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in\u00a0BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity"],"prefix":"10.1016","volume":"4","author":[{"given":"Brian","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afaf E.G.","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Sladojevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haw-Chih","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Perla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2022.06.004_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2022.06.004_bib2","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic\u00a0phase treated with imatinib, nilotinib,\u00a0or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2022.06.004_bib3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.06.004_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2022.06.004_bib5","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2022.06.004_bib6","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2022.06.004_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092146","article-title":"Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use","volume":"9","author":"Uitdehaag","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaccao.2022.06.004_bib8","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaccao.2022.06.004_bib9","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1523\/JNEUROSCI.0793-07.2007","article-title":"Inhibition of Rho via Arg and p190RhoGAP in the postnatal mouse hippocampus regulates dendritic spine maturation, synapse and dendrite stability, and behavior","volume":"27","author":"Sfakianos","year":"2007","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.jaccao.2022.06.004_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14728222.2020.1712593","article-title":"Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening","volume":"24","author":"Yu","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jaccao.2022.06.004_bib11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/14737175.2017.1395700","article-title":"ROCK as a therapeutic target for ischemic stroke","volume":"17","author":"Sladojevic","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.jaccao.2022.06.004_bib12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.273.5272.245","article-title":"Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase)","volume":"273","author":"Kimura","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2022.06.004_bib13","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jacc.2006.06.082","article-title":"Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness","volume":"49","author":"Noma","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.06.004_bib14","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2006.12.043","article-title":"Increased Rho kinase activity in a Taiwanese population with metabolic syndrome","volume":"49","author":"Liu","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.06.004_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaccao.2022.06.004_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1172\/JCI9639","article-title":"Neuroprotection mediated by changes in the endothelial actin cytoskeleton","volume":"106","author":"Laufs","year":"2000","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaccao.2022.06.004_bib17","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1253\/circj.CJ-17-0732","article-title":"Neuroprotection mediated by upregulation of endothelial nitric oxide synthase in Rho-associated, coiled-coil-containing kinase 2 deficient mice","volume":"82","author":"Hiroi","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jaccao.2022.06.004_bib18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.bbrc.2007.07.030","article-title":"Rho-kinase phosphorylates eNOS at threonine 495 in endothelial cells","volume":"361","author":"Sugimoto","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaccao.2022.06.004_bib19","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.1128\/MCB.22.24.8467-8477.2002","article-title":"Rho GTPase\/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B\/Akt in human endothelial cells","volume":"22","author":"Ming","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jaccao.2022.06.004_bib20","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.06.004_bib21","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/eurjhf\/hfs068","article-title":"Increased Rho kinase activity in congestive heart failure","volume":"14","author":"Dong","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaccao.2022.06.004_bib22","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1161\/01.RES.0000251668.39526.c7","article-title":"Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease","volume":"99","author":"Nohria","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.jaccao.2022.06.004_bib23","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/sj.onc.1210841","article-title":"The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation","volume":"27","author":"Sahay","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.jaccao.2022.06.004_bib24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clml.2016.01.006","article-title":"Mortality and vascular events among elderly patients with chronic myeloid leukemia: a retrospective analysis of linked SEER-Medicare data","volume":"16","author":"Lang","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jaccao.2022.06.004_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/srep30832","article-title":"Imatinib binding to human c-Src is coupled to inter-domain allostery and suggests a novel kinase inhibition strategy","volume":"6","author":"Tsutsui","year":"2016","journal-title":"Sci Rep"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322003106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322003106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:54:36Z","timestamp":1762973676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087322003106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2666087322003106"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.06.004","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in\u00a0BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}